Baird R W Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Strong-Buy

Baird R W upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) to a strong-buy rating in a report published on Friday morning, Zacks.com reports.

Other equities analysts have also issued reports about the stock. Wedbush upped their price objective on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an outperform rating in a report on Friday, May 10th. Lifesci Capital raised Dianthus Therapeutics to a strong-buy rating in a research note on Tuesday, June 11th. HC Wainwright initiated coverage on Dianthus Therapeutics in a research note on Thursday, May 16th. They set a buy rating and a $40.00 target price on the stock. Cantor Fitzgerald started coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an overweight rating for the company. Finally, Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research report on Friday. They set an outperform rating and a $58.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Buy and a consensus price target of $45.00.

Dianthus Therapeutics Stock Performance

DNTH opened at $28.97 on Friday. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The stock has a market capitalization of $850.27 million, a PE ratio of -4.97 and a beta of 1.89. The business’s 50 day moving average price is $25.27 and its 200 day moving average price is $24.08.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The company had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $0.48 million. As a group, equities research analysts forecast that Dianthus Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC purchased a new position in Dianthus Therapeutics in the first quarter valued at $89,761,000. RA Capital Management L.P. acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $69,990,000. Vanguard Group Inc. increased its holdings in shares of Dianthus Therapeutics by 250.0% in the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth about $11,251,000. Finally, Vestal Point Capital LP purchased a new stake in Dianthus Therapeutics during the fourth quarter worth approximately $1,404,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.